Clinical Roundup COVID-19 pandemic associated with decline in number of reported cancer cases October 27, 2023Vol.49 No.40
Clinical Roundup Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC October 27, 2023Vol.49 No.40
Clinical Roundup Imfinzi + chemo more than doubled pathologic CRR in gastric, gastroesophageal junction cancers October 27, 2023Vol.49 No.40
Clinical Roundup DUO-E phase III trial: Imfinzi + Lynparza reduces risk of progression/death vs. chemo in advanced/recurrent endometrial cancer October 27, 2023Vol.49 No.40
Clinical Roundup Phase III NATALEE trial: Kisqali demonstrates risk of recurrence in early breast cancer October 27, 2023Vol.49 No.40
Clinical Roundup Phase III PSMAfore trial: Pluvicto demonstrates clinically meaningful rPFS benefit in prostate cancer October 27, 2023Vol.49 No.40
Clinical Roundup Phase III ALINA study: Alecensa reduces risk of disease recurrence/death in NSCLC October 27, 2023Vol.49 No.40
Clinical Roundup UTSW: Emergency room visits by cancer patients can often be avoided October 27, 2023Vol.49 No.40
Clinical Roundup NCI-designated subspecialist reviews improve 94% of pancreatic cancer treatment paths October 27, 2023Vol.49 No.40
Clinical Roundup UC Davis researchers identify “switch” to activate cancer cell death October 27, 2023Vol.49 No.40
